GEN Exclusives

More »

GEN News Highlights

More »
Sep 7, 2007

Ablynx and Boehringer Ingelheim Sign EUR 200M Nanobody Alliance

  • Boehringer Ingelheim and Ablynx inked a Nanobody® therapeutics deal potentially worth over EUR 200 million for the latter company. The global strategic alliance will cover discover, develop, and commercialize up to 10 nanobody therapeutics.

    Ablynx expects to receive payments of EUR 75 million during the research term of the collaboration. This includes EUR 15 million in a proposed equity investment. Ablynx also will receive development milestone fees for each Nanobody® that is developed up to EUR 125 million, as well as undisclosed royalties.

    Ablynx and Boehringer Ingelheim will collaborate in the discovery of  nanobodies against agreed targets across multiple therapeutic areas including  immunology, oncology, and respiratory. Both parties will propose target opportunities.

    Boehringer Ingelheim will be exclusively  responsible for the development, manufacture, and commercialization of any products resulting from the partnership. Ablynx will have certain co-promotion rights in Europe.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?